RESUMO
Purpose@#Granular corneal dystrophy type 1 (GCD1) is a genetic disorder characterized by grayish-white granular deposits in the corneal stroma, typically manifesting before age 10. The specific characteristics of GCD1 in the Korea population remain insufficiently described. This study investigated the morphological features of GCD1 corneas with confirmed genetic mutations in this population. @*Methods@#Medical records of GCD1 patients with the R555W mutation confirmed through transforming growth factor β induced (TGFBI) gene testing on oral epithelium or blood samples from 2005-2022, were analyzed. Corneal photographs obtained using a slit lamp biomicroscope were also examined. @*Results@#The study group included 11 males and 19 females with an average age of 35.7 years, ranging from 3-70 years. All participants were heterozygotes. In 28 individuals (56 eyes, representing 93.3% of the total), there were signs of corneal deposit detachments, known as “drop-off”, observed in patients aged 6 years and above. Surface deposits reemerged at the peripheral margin of previous locations and expanded toward the center. The number and shape of opacities significantly changed with age, showing cycles of deposition and shedding. There were variations in the severity of opacities within the same family, particularly with advancing age, and distinct opacities extending into deeper stromal layers. @*Conclusions@#This study outlines the morphological characteristics of corneas in Korean GCD1 patients, based on corneal photograph analysis. These findings provide a basis for future comparative studies with GCD2 and may aid rapid clinical diagnosis based on clinical findings, prior to genetic testing confirmation.
RESUMO
PURPOSE: To investigate the difference of optical coherence tomography (OCT) findings between the aflibercept treatment group and the ranibizumab treatment group. METHODS: This study includes patients diagnosed with treatment-naïve neovascular age-related macular degeneration (AMD), and they were treated with aflibercept (n = 23, 23 eyes) or ranibizumab (n = 26, 26 eyes) monthly for 3 months. In this study, the aflibercept treatment group patients were treated from March 2014 to April 2015, and the ranibizumab treatment group patients were treated from December 2008 to April 2015. After three initial injections, they were followed up monthly for an additional 3 months, and additional treatments were performed if necessary. We compared the changes of the two groups before the treatment and after 6 months of treatment, beginning with the OCT findings, such as serous pigment epithelium detachment, fibrovascular pigment epithelium detachment, subretinal fluid, intraretinal fluid, dense zone of outer retina, classic neovascularization, and hyper- reflective dots. We also compared the changes of best corrected visual acuity (BCVA) and inner segment/outer segment (IS/OS) length, external limiting membrane length, and central foveal thickness with optical OCT between the two groups. RESULTS: In the aflibercept group, 46% of serous epithelial detachments disappeared, while 33% disappeared in the ranibizumab group, and there was significant difference between the two groups (p = 0.01). There was no significant difference in BCVA change or OCT findings between the two groups, but there was a significant difference in serous pigment epithelium detachment. CONCLUSIONS: For treatment of neovascular AMD patients, aflibercept might be more effective in serous pigment epithelium detachment than ranibizumab. Because there was no significant difference in visual acuity improvement in serous pigment detachment for both treatments, it might be necessary to further study the relationship between visual acuity and serous pigment detachment improvement.